Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Philip Kantoff, M.D.

Co-Author

This page shows the publications co-authored by Philip Kantoff and Lorelei Mucci.
Connection Strength

7.513
  1. Is the Evidence Sufficient to Recommend Statins for All Men With Prostate Cancer? J Clin Oncol. 2017 10 10; 35(29):3272-3274.
    View in: PubMed
    Score: 0.744
  2. Polymorphism in endostatin, an angiogenesis inhibitor, and prostate cancer risk and survival: A prospective study. Int J Cancer. 2009 Sep 01; 125(5):1143-6.
    View in: PubMed
    Score: 0.428
  3. Differences in prostate cancer genomes by self-reported race: Contributions of genetic ancestry, modifiable cancer risk factors, and clinical factors. Clin Cancer Res. 2021 Oct 19.
    View in: PubMed
    Score: 0.248
  4. Tackling Diversity in Prostate Cancer Clinical Trials: A Report From the Diversity Working Group of the IRONMAN Registry. JCO Glob Oncol. 2021 04; 7:495-505.
    View in: PubMed
    Score: 0.239
  5. Attenuation of SRC Kinase Activity Augments PARP Inhibitor-mediated Synthetic Lethality in BRCA2-altered Prostate Tumors. Clin Cancer Res. 2021 03 15; 27(6):1792-1806.
    View in: PubMed
    Score: 0.234
  6. Tumor protein expression of the DNA repair gene BRCA1 and lethal prostate cancer. Carcinogenesis. 2020 07 14; 41(7):904-908.
    View in: PubMed
    Score: 0.227
  7. Diversity of Enrollment in Prostate Cancer Clinical Trials: Current Status and Future Directions. Cancer Epidemiol Biomarkers Prev. 2020 07; 29(7):1374-1380.
    View in: PubMed
    Score: 0.226
  8. TMPRSS2 and COVID-19: Serendipity or Opportunity for Intervention? Cancer Discov. 2020 06; 10(6):779-782.
    View in: PubMed
    Score: 0.223
  9. Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression. Clin Cancer Res. 2020 04 15; 26(8):2047-2064.
    View in: PubMed
    Score: 0.218
  10. Statin Use Is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer. Clin Cancer Res. 2020 03 01; 26(5):1086-1093.
    View in: PubMed
    Score: 0.217
  11. Intratumoral Sterol-27-Hydroxylase (CYP27A1) Expression in Relation to Cholesterol Synthesis and Vitamin D Signaling and Its Association with Lethal Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2019 06; 28(6):1052-1058.
    View in: PubMed
    Score: 0.207
  12. Low Expression of the Androgen-Induced Tumor Suppressor Gene PLZF and Lethal Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2019 04; 28(4):707-714.
    View in: PubMed
    Score: 0.205
  13. Association of genetic variation of the six gene prognostic model for castration-resistant prostate cancer with survival. Prostate. 2019 01; 79(1):73-80.
    View in: PubMed
    Score: 0.199
  14. Regular aspirin use and gene expression profiles in prostate cancer patients. Cancer Causes Control. 2018 Aug; 29(8):775-784.
    View in: PubMed
    Score: 0.197
  15. ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D. J Clin Invest. 2018 07 02; 128(7):2979-2995.
    View in: PubMed
    Score: 0.196
  16. The impact of statin use on the efficacy of abiraterone acetate in patients with castration-resistant prostate cancer. Prostate. 2017 May; 77(13):1303-1311.
    View in: PubMed
    Score: 0.185
  17. Gene expression profiling of prostate tissue identifies chromatin regulation as a potential link between obesity and lethal prostate cancer. Cancer. 2017 Nov 01; 123(21):4130-4138.
    View in: PubMed
    Score: 0.185
  18. The role of tumor metabolism as a driver of prostate cancer progression and lethal disease: results from a nested case-control study. Cancer Metab. 2016; 4:22.
    View in: PubMed
    Score: 0.177
  19. Selenium- or Vitamin E-Related Gene Variants, Interaction with Supplementation, and Risk of High-Grade Prostate Cancer in SELECT. Cancer Epidemiol Biomarkers Prev. 2016 07; 25(7):1050-1058.
    View in: PubMed
    Score: 0.170
  20. Association of genetic variations of selenoprotein genes, plasma selenium levels, and prostate cancer aggressiveness at diagnosis. Prostate. 2016 May; 76(7):691-9.
    View in: PubMed
    Score: 0.167
  21. Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer. JAMA Oncol. 2015 Jul; 1(4):495-504.
    View in: PubMed
    Score: 0.160
  22. GermLine Variation in Superoxide Dismutase-2 (SOD2) and Survival Outcomes After Radiation Therapy for Prostate Cancer: Results of a Test and Validation Set Analysis. Clin Genitourin Cancer. 2015 Aug; 13(4):370-377.e1.
    View in: PubMed
    Score: 0.155
  23. Androgen receptor CAG repeat polymorphism and risk of TMPRSS2:ERG-positive prostate cancer. Cancer Epidemiol Biomarkers Prev. 2014 Oct; 23(10):2027-31.
    View in: PubMed
    Score: 0.149
  24. SPINK1 protein expression and prostate cancer progression. Clin Cancer Res. 2014 Sep 15; 20(18):4904-11.
    View in: PubMed
    Score: 0.147
  25. Modification of the association between obesity and lethal prostate cancer by TMPRSS2:ERG. J Natl Cancer Inst. 2013 Dec 18; 105(24):1881-90.
    View in: PubMed
    Score: 0.144
  26. Associations between single nucleotide polymorphisms (SNPs) in inflammation-related genes and quality of life after radiation therapy (RT) for prostate cancer. J Clin Oncol. 2013 Feb 20; 31(6_suppl):2.
    View in: PubMed
    Score: 0.136
  27. A single nucleotide polymorphism in inflammatory gene RNASEL predicts outcome after radiation therapy for localized prostate cancer. Clin Cancer Res. 2013 Mar 15; 19(6):1612-9.
    View in: PubMed
    Score: 0.136
  28. The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2012 Sep; 21(9):1497-509.
    View in: PubMed
    Score: 0.130
  29. mRNA expression signature of Gleason grade predicts lethal prostate cancer. J Clin Oncol. 2011 Jun 10; 29(17):2391-6.
    View in: PubMed
    Score: 0.120
  30. Immunohistochemical expression of BRCA1 and lethal prostate cancer. Cancer Res. 2010 Apr 15; 70(8):3136-9.
    View in: PubMed
    Score: 0.112
  31. Effects of G/A polymorphism, rs266882, in the androgen response element 1 of the PSA gene on prostate cancer risk, survival and circulating PSA levels. Br J Cancer. 2008 Nov 18; 99(10):1743-7.
    View in: PubMed
    Score: 0.100
  32. Testing a multigene signature of prostate cancer death in the Swedish Watchful Waiting Cohort. Cancer Epidemiol Biomarkers Prev. 2008 Jul; 17(7):1682-8.
    View in: PubMed
    Score: 0.099
  33. Nine-gene molecular signature is not associated with prostate cancer death in a watchful waiting cohort. Cancer Epidemiol Biomarkers Prev. 2008 Jan; 17(1):249-51.
    View in: PubMed
    Score: 0.095
  34. Novel genomic signature predictive of response to immune checkpoint blockade: A pan-cancer analysis from project Genomics Evidence Neo-plasia Information Exchange (GENIE). Cancer Genet. 2021 Aug 28; 258-259:61-68.
    View in: PubMed
    Score: 0.061
  35. Racial Differences in Genomic Profiling of Prostate Cancer. N Engl J Med. 2020 09 10; 383(11):1083-1085.
    View in: PubMed
    Score: 0.057
  36. Multiplex Immunofluorescence in Formalin-Fixed Paraffin-Embedded Tumor Tissue to Identify Single-Cell-Level PI3K Pathway Activation. Clin Cancer Res. 2020 11 15; 26(22):5903-5913.
    View in: PubMed
    Score: 0.057
  37. High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program. Nat Commun. 2019 09 25; 10(1):4358.
    View in: PubMed
    Score: 0.054
  38. Family history of prostate cancer and the incidence of ERG- and phosphatase and tensin homolog-defined prostate cancer. Int J Cancer. 2020 05 15; 146(10):2694-2702.
    View in: PubMed
    Score: 0.053
  39. Aneuploidy drives lethal progression in prostate cancer. Proc Natl Acad Sci U S A. 2019 06 04; 116(23):11390-11395.
    View in: PubMed
    Score: 0.052
  40. A Prospective Study of Aspirin Use and Prostate Cancer Risk by TMPRSS2:ERG Status. Cancer Epidemiol Biomarkers Prev. 2018 10; 27(10):1231-1233.
    View in: PubMed
    Score: 0.050
  41. The ABC model of prostate cancer: A conceptual framework for the design and interpretation of prognostic studies. Cancer. 2017 05 01; 123(9):1490-1496.
    View in: PubMed
    Score: 0.045
  42. Overexpression of the Long Non-coding RNA SChLAP1 Independently Predicts Lethal Prostate Cancer. Eur Urol. 2016 10; 70(4):549-552.
    View in: PubMed
    Score: 0.041
  43. Measuring PI3K Activation: Clinicopathologic, Immunohistochemical, and RNA Expression Analysis in Prostate Cancer. Mol Cancer Res. 2015 Oct; 13(10):1431-40.
    View in: PubMed
    Score: 0.040
  44. Role of diet in prostate cancer: the epigenetic link. Oncogene. 2015 Sep 03; 34(36):4683-91.
    View in: PubMed
    Score: 0.039
  45. Elevated IL-8, TNF-a, and MCP-1 in men with metastatic prostate cancer starting androgen-deprivation therapy (ADT) are associated with shorter time to castration-resistance and overall survival. Prostate. 2014 Jun; 74(8):820-8.
    View in: PubMed
    Score: 0.037
  46. Elevated insulin-like growth factor binding protein-1 (IGFBP-1) in men with metastatic prostate cancer starting androgen deprivation therapy (ADT) is associated with shorter time to castration resistance and overall survival. Prostate. 2014 Feb; 74(3):225-34.
    View in: PubMed
    Score: 0.036
  47. Vitamin D receptor protein expression in tumor tissue and prostate cancer progression. J Clin Oncol. 2011 Jun 10; 29(17):2378-85.
    View in: PubMed
    Score: 0.030
  48. Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis. PLoS Genet. 2010 Nov 11; 6(11):e1001204.
    View in: PubMed
    Score: 0.029
  49. Genome-wide association study of prostate cancer mortality. Cancer Epidemiol Biomarkers Prev. 2010 Nov; 19(11):2869-76.
    View in: PubMed
    Score: 0.029
  50. A large prospective study of SEP15 genetic variation, interaction with plasma selenium levels, and prostate cancer risk and survival. Cancer Prev Res (Phila). 2010 May; 3(5):604-10.
    View in: PubMed
    Score: 0.028
  51. Molecular sampling of prostate cancer: a dilemma for predicting disease progression. BMC Med Genomics. 2010 Mar 16; 3:8.
    View in: PubMed
    Score: 0.028
  52. Evaluation of the 8q24 prostate cancer risk locus and MYC expression. Cancer Res. 2009 Jul 01; 69(13):5568-74.
    View in: PubMed
    Score: 0.026
  53. Evaluation of 8q24 and 17q risk loci and prostate cancer mortality. Clin Cancer Res. 2009 May 01; 15(9):3223-30.
    View in: PubMed
    Score: 0.026
  54. No association between a polymorphic variant of the IRS-1 gene and prostate cancer risk. Prostate. 2008 Sep 15; 68(13):1416-20.
    View in: PubMed
    Score: 0.025
  55. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst. 2008 Jun 04; 100(11):815-25.
    View in: PubMed
    Score: 0.025
  56. Prostate cancer risk and ESR1 TA, ESR2 CA repeat polymorphisms. Cancer Epidemiol Biomarkers Prev. 2007 Nov; 16(11):2233-6.
    View in: PubMed
    Score: 0.024
  57. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene. 2007 Jul 05; 26(31):4596-9.
    View in: PubMed
    Score: 0.022
  58. Decreased alpha-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death. Cancer Epidemiol Biomarkers Prev. 2005 Jun; 14(6):1424-32.
    View in: PubMed
    Score: 0.020
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.